Atrium Therapeutics says ATR 1072 mouse surrogate reverses cardiac glycogen buildup in preclinical study

PUBT · 1d ago
Atrium Therapeutics says ATR 1072 mouse surrogate reverses cardiac glycogen buildup in preclinical study
  • Atrium Therapeutics will present nonclinical ATR 1072 data for PRKAG2 syndrome Nov. 6, 2026, at American Heart Association Scientific Sessions.
  • A single dose of a mouse version reversed cardiac glycogen accumulation in a disease model, improving heart enlargement and ECG abnormalities.
  • The ongoing Phase 1/2 Corventis trial is expected to deliver initial proof-of-concept data in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611020630PR_NEWS_USPR_____LA86165) on November 02, 2026, and is solely responsible for the information contained therein.